Recombinant Human ACVRL1 Protein，His

ACVRL1, or Activin A receptor type II-like 1, is a key component of the TGF-beta superfamily of receptors, crucial for various biological processes, including vascular development, cell proliferation, and differentiation. Mutations in the ACVRL1 gene are linked to hereditary hemorrhagic telangiectasia (HHT), a genetic disorder characterized by abnormal blood vessel formation, leading to frequent nosebleeds, gastrointestinal bleeding, and arteriovenous malformations. Research on ACVRL1 recombinant proteins has gained significant attention due to their potential therapeutic applications in targeting vascular abnormalities and modulating angiogenesis. Understanding the structure and function of ACVRL1 is essential for elucidating its role in disease pathology and for developing targeted treatments for conditions associated with dysfunctional vascular system regulation. The production of recombinant ACVRL1 proteins allows for in-depth studies of receptor signaling pathways and interaction with ligands, providing insights into the molecular mechanisms underlying HHT and other vascular disorders. Moreover, recombinant ACVRL1 can serve as a valuable tool in drug screening and the identification of novel compounds that can enhance or inhibit its activity, which may lead to innovative therapeutic strategies for managing vascular-related diseases. Through these investigations, researchers aim to improve our understanding of ACVRL1’s involvement in both normal physiology and pathological conditions, ultimately contributing to the advancement of clinical interventions for patients suffering from HHT and associated vascular malformations.